Olaparib’s out-of-pocket purchase price and medical insurance coverage in 2025

Olaparib (Olaparib) is a PARP inhibitor drug used for BRCA gene mutation-related ovarian cancer, breast cancer and other tumors. It has been officially launched in China and has been included in the medical insurance system. Patients can purchase the drug through regular domestic hospital pharmacies and enjoy the medical insurance reimbursement policy. The inclusion of Lynparza in medical insurance provides certain financial relief to eligible patients, but the specific reimbursement ratio and payment amount depend on the patient's region and medical insurance policy. Therefore, it is recommended to consult the local hospital or pharmacy for detailed information before purchasing the drug.

In the domestic market, the common specifications of Lynparza are150mg*56 tablets, and the price is about four to five thousand yuan. Because it is an imported original drug, its price is relatively high, but the stability of the efficacy and the reliability of the drug ingredients are guaranteed. This price range provides patients with a clear self-pay reference, making it easier for patients and their families to make an economic budget for medication in advance.

For overseas markets, the prices of Lynparza vary greatly. There are mainly Bangladeshi and Laos versions of generic drugs on the foreign market, with a specification of 150mg*120 tablets and a price of about 2,000 yuan, which is much cheaper than domestic original drugs. It should be noted that the ingredients of these generic drugs are basically the same as those of the original drugs, but it is necessary to confirm the formal channels when purchasing to ensure the safety and effectiveness of the drugs.

Overall, the domestic launch of Lynparza and medical insurance coverage provide patients with regular drug purchasing channels and financial support, while the lower prices of overseas generic drugs provide an alternative for patients who need to purchase drugs overseas. During the actual medication process, patients should reasonably choose purchasing channels based on their own economic conditions, medical insurance policies and clinician recommendations, and strictly follow the doctor's guidance for medication management to ensure efficacy and medication safety.

Reference materials:https://www.drugs.com/